Cargando…

Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients

Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admis...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahaj, Edison, Vassiliou, Alice G., Keskinidou, Chrysi, Gallos, Parisis, Vrettou, Charikleia S., Tsipilis, Stamatios, Mastora, Zafeiria, Orfanos, Stylianos E., Dimopoulou, Ioanna, Kotanidou, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466794/
https://www.ncbi.nlm.nih.gov/pubmed/34575667
http://dx.doi.org/10.3390/jpm11090891
_version_ 1784573231114485760
author Jahaj, Edison
Vassiliou, Alice G.
Keskinidou, Chrysi
Gallos, Parisis
Vrettou, Charikleia S.
Tsipilis, Stamatios
Mastora, Zafeiria
Orfanos, Stylianos E.
Dimopoulou, Ioanna
Kotanidou, Anastasia
author_facet Jahaj, Edison
Vassiliou, Alice G.
Keskinidou, Chrysi
Gallos, Parisis
Vrettou, Charikleia S.
Tsipilis, Stamatios
Mastora, Zafeiria
Orfanos, Stylianos E.
Dimopoulou, Ioanna
Kotanidou, Anastasia
author_sort Jahaj, Edison
collection PubMed
description Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admission to the intensive care unit (ICU) in critically ill COVID-19 (N = 38) and critically ill non-COVID-19 (N = 34) patients with an equal critical illness severity. Critically ill non-COVID-19 patients did not have sepsis or septic shock on ICU admission. None of the enrolled patients had previously received corticosteroids. In our study, circulating IL-17 levels were higher in the COVID-19 patients. More specifically, critically ill COVID-19 patients had levels of 0.78 (0.05–1.8) pg/mL compared to 0.11 (0.05–0.9) pg/mL in the critically ill non-COVID-19 patients (p = 0.04). In contrast, IL-23 levels were comparable between groups. A group of patients hospitalized in the specialized COVID-19 clinic (N = 16) was also used to evaluate IL-17 and IL-23 levels with respect to COVID-19 severity. Non-critically ill COVID-19 patients had undetectable levels of both cytokines. Our results support the notion of inhibiting IL-17 in critical COVID-19 infection.
format Online
Article
Text
id pubmed-8466794
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84667942021-09-27 Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients Jahaj, Edison Vassiliou, Alice G. Keskinidou, Chrysi Gallos, Parisis Vrettou, Charikleia S. Tsipilis, Stamatios Mastora, Zafeiria Orfanos, Stylianos E. Dimopoulou, Ioanna Kotanidou, Anastasia J Pers Med Communication Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admission to the intensive care unit (ICU) in critically ill COVID-19 (N = 38) and critically ill non-COVID-19 (N = 34) patients with an equal critical illness severity. Critically ill non-COVID-19 patients did not have sepsis or septic shock on ICU admission. None of the enrolled patients had previously received corticosteroids. In our study, circulating IL-17 levels were higher in the COVID-19 patients. More specifically, critically ill COVID-19 patients had levels of 0.78 (0.05–1.8) pg/mL compared to 0.11 (0.05–0.9) pg/mL in the critically ill non-COVID-19 patients (p = 0.04). In contrast, IL-23 levels were comparable between groups. A group of patients hospitalized in the specialized COVID-19 clinic (N = 16) was also used to evaluate IL-17 and IL-23 levels with respect to COVID-19 severity. Non-critically ill COVID-19 patients had undetectable levels of both cytokines. Our results support the notion of inhibiting IL-17 in critical COVID-19 infection. MDPI 2021-09-07 /pmc/articles/PMC8466794/ /pubmed/34575667 http://dx.doi.org/10.3390/jpm11090891 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Jahaj, Edison
Vassiliou, Alice G.
Keskinidou, Chrysi
Gallos, Parisis
Vrettou, Charikleia S.
Tsipilis, Stamatios
Mastora, Zafeiria
Orfanos, Stylianos E.
Dimopoulou, Ioanna
Kotanidou, Anastasia
Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
title Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
title_full Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
title_fullStr Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
title_full_unstemmed Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
title_short Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients
title_sort evaluating the role of the interleukin-23/17 axis in critically ill covid-19 patients
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466794/
https://www.ncbi.nlm.nih.gov/pubmed/34575667
http://dx.doi.org/10.3390/jpm11090891
work_keys_str_mv AT jahajedison evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT vassilioualiceg evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT keskinidouchrysi evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT gallosparisis evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT vrettoucharikleias evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT tsipilisstamatios evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT mastorazafeiria evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT orfanosstylianose evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT dimopoulouioanna evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients
AT kotanidouanastasia evaluatingtheroleoftheinterleukin2317axisincriticallyillcovid19patients